Lupus Nephritis: A Different Disease in European Patients? | Zendy

Vladimı́r Tesař | Zendy; Zdenka Hrušková | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Lupus Nephritis: A Different Disease in European Patients?

Author(s) -

Vladimı́r Tesař,

Zdenka Hrušková

Publication year - 2015

Publication title -

kidney diseases

Language(s) - English

Resource type - Journals

eISSN - 2296-9381

pISSN - 2296-9357

DOI - 10.1159/000438844

Subject(s) - medicine , lupus nephritis , rituximab , belimumab , cyclophosphamide , ethnic group , disease , systemic lupus erythematosus , immunology , gastroenterology , chemotherapy , lymphoma , b cell activating factor , b cell , antibody , sociology , anthropology

Lupus nephritis (LN) is still associated with significant mortality and substantial risk of progression to end-stage renal failure. Its outcome is related to the class and severity of LN and response to treatment, and it is poorer in patients with renal relapses. Ethnicity has a relatively well-defined impact on the outcome of the patients and their response to treatment and must always be taken into consideration in treatment decisions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research